VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump? IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%. | ||
 Vanda (VNDA) Q2 2026 Earnings Call Transcript Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress. | ||
 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs. | ||
 Vanda Pharmaceuticals Q2 Earnings Call Highlights Vanda Pharmaceuticals (NASDAQ:VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it exp | ||
 Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary Moby summary of Vanda Pharmaceuticals Inc.'s Q2 2026 earnings call | ||
 Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||